Multimodal treatment of gastric cancer in the west: Where are we going?

Table 1 Main trials regarding adjuvant and neoadjuvant therapy for gastric cancer reported in literature

Trial name	Therapy	Treatment arms	Tumor position	OS P vaule	PFS/DFS P vaule
Neoadjuvant CT
MAGIC[48]	CT	Perioperative	GC + EGJ	0.009	< 0.001
		Res. vs mult
FNLCC/FFCD 9703[49]	CT	Perioperative	GC + EGJ	0.021	0.003
		Res. vs mult
EORTC 40954[50]	CT	Preoperative	GC + EGJ	0.466 NS	0.200
		Res. vs mult			NS
Neoadjuvant CRT
POET[51]	CRT	Preoperative	EGJ (I, II, III)	0.07	0.060
		CRT vs mult CT		NS (3 yr)	NS (3 yr)
CROSS[52]	CRT	Preoperative	Esophagus + EGJ I, II, III	0.003	< 0.001
		Res. vs mult CRT
Adjuvant CT
ACTS-GC[53,54]	CT	Postoperative	Not given	0.002	< 0.001
		Res. vs mult
CLASSIC[65]	CT	Postoperative	GC + EGJ	0.049	< 0.0001
		Res. vs mult		(3 yr)	(3 yr)
Adjuvant CRT
INT 0116[55]	CRT	Postoperative	GC + EGJ	0.005	< 0.001
		Res. vs mult
ARTIST[72]	CRT	Postoperative	GC	Not given	0.0824
		Res. vs mult			NS (3 yr)

CT: Chemotherapy; CRT: Chemoradiotherapy; GC: Gastric; EGJ: Esophageal gastric junction; OS: Overall survival; PFS/DFS: Progression-free survival/disease-free survival; Mult: Multimodal treatment; Res: Surgical resection alone.